TMeds

TMeds is a clinical-stage biotechnology company specializing in the development of oral delivery systems for peptides and proteins. The company's proprietary T-Meds platform utilizes a unique carrier system to protect biologics from gastrointestinal degradation and facilitate their absorption into the bloodstream. Its primary focus is on metabolic diseases, with a lead candidate, T-Meds 001, which is an oral insulin formulation currently in clinical development. By converting injectable therapies into oral dosages, TMeds aims to significantly improve patient adherence and quality of life for those suffering from chronic conditions like diabetes and obesity. The company is a spin-off from Taipei Medical University and is headquartered in Hsinchu, Taiwan.